Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases.

ABSTRACT:

Background

Patients with initially unresectable colorectal cancer liver metastases (IU-CRLM) might benefit from using an effective systemic treatment followed by resection of liver metastases but the curative success rate is quite low. Indeed, nearly one-third of patients exhibit early recurrence within the first 6 months after surgery, and these individuals often have poor overall survival.

Objectives

This study aims to clarify the application value of serial circulating tumor DNA (ctDNA) analysis in predicting the clinical outcome of IU-CRLM patients following liver metastasectomy.

Design

A retrospective study was conducted on a cohort of patients with IU-CRLM between February 2018 and April 2021.

Methods

Plasma samples at different time points during CRLM tr

SUBMITTER: Chen ZG 

PROVIDER: S-EPMC10903215 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature